Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €190.12 EUR
Change Today -2.92 / -1.51%
Volume 245.0
BVF On Other Exchanges
Symbol
Exchange
Toronto
New York
Mexico
Frankfurt
As of 11:22 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (BVF) Snapshot

Open
€192.42
Previous Close
€193.04
Day High
€195.80
Day Low
€190.12
52 Week High
04/13/15 - €200.23
52 Week Low
08/8/14 - €78.82
Market Cap
63.7B
Average Volume 10 Days
473.9
EPS TTM
--
Shares Outstanding
335.0M
EX-Date
11/10/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALEANT PHARMACEUTICALS INTE (BVF)

valeant pharmaceuticals inte (BVF) Details

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

16,800 Employees
Last Reported Date: 02/25/15
Founded in 1983

valeant pharmaceuticals inte (BVF) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.9M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $953.8K
President of Valeant Europe and General Manag...
Total Annual Compensation: $499.3K
Executive Vice President and Company Group Ch...
Total Annual Compensation: $5.8M
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $715.4K
Compensation as of Fiscal Year 2014.

valeant pharmaceuticals inte (BVF) Key Developments

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. Announces RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

April 24, 2015 Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for RELISTOR, to 11 years from the date of approval, citing the fact that RELISTOR offers a major contribution to patient care in comparison to existing therapies. The CHMP is responsible for reviewing medicinal product applications for safety, quality and efficacy. The CHMP's positive opinion on RELISTOR will be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The final decision will be applicable to all 28 European Union member countries plus Iceland and Norway. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic non-cancer pain.

Allergan Inc. Drops Suit Filed Against Valeant Pharmaceuticals International Inc. and Pershing Square Capital Management, L.P

Allergan Inc. ended its court battle with Valeant Pharmaceuticals International Inc. and Bill Ackman's Pershing Square Capital Management LP over an attempted takeover of the maker of the facial wrinkle-fighter Botox. The combatants filed papers in U.S. federal court in which Allergan dropped its lawsuit against Valeant and Pershing and they reciprocated by surrendering their claims.

Valeant Pharmaceuticals International Announces Board Changes

In connection with the Merger, at the effective time of the Merger, each of the directors of Salix Pharmaceuticals Ltd. (John F. Chappell, Thomas W. D'Alonzo, William P. Keane and Mark A. Sirgo) resigned as directors of Salix and from all committees of the board of directors of company, and the directors of Purchaser, consisting of J. Michael Pearson, Howard B. Schiller and Robert R. Chai-Onn, became directors of the Valeant Pharmaceuticals International. At the Effective Time, each of the officers of Salix (Mr. D'Alonzo, William C. Bertrand, Jr., William P. Forbes, Timothy J. Creech and Rick D. Scruggs) resigned or was removed from their respective offices. Immediately thereafter, Messrs. Pearson, Schiller and Chai-Onn were appointed as the executive officers of the Valeant Pharmaceuticals International.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BVF:GR €190.12 EUR -2.92

BVF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,934 JPY -14.50
Mylan NV $72.12 USD -3.94
Perrigo Co PLC $190.28 USD -2.61
Sun Pharmaceutical Industries Ltd 926.40 INR -21.00
Teva Pharmaceutical Industries Ltd $62.34 USD -2.07
View Industry Companies
 

Industry Analysis

BVF

Industry Average

Valuation BVF Industry Range
Price/Earnings 78.6x
Price/Sales 8.5x
Price/Book 13.2x
Price/Cash Flow 30.1x
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit www.valeant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.